Table 1.
Patients’ characteristics.
| n | % | |
|---|---|---|
| Gender: | ||
| • Male | 11 | 92 |
| • Female | 1 | 8 |
| Median age (range); years | 74 (46–82) | |
| ECOG performance status: | ||
| • 0 | 2 | 17 |
| • 1 | 9 | 75 |
| • 2 | 1 | 8 |
| Primary localization: | ||
| • H&N | 10 | 83 |
| • Gluteal region | 2 | 17 |
| Local disease: | ||
| • No local recurrence | 1 | 8 |
| • T1 | 0 | 0 |
| • T2 | 3 | 25 |
| • T3 | 6 | 50 |
| • T4 | 1 | 8 |
| • NA | 1 | 8 |
| Node involvement: | ||
| • N0 | 5 | 42 |
| • N1 | 3 | 25 |
| • N2 | 3 | 25 |
| • NA | 1 | 8 |
| Metastatic at treatment start | 4 | 33 |
| Histotype: | ||
| • Histological subtypes of SCC | 12 | 100 |
| ○ Invasive SCC | 9 | 75 |
| ○ Poorly differentiated SCC | 1 | 8 |
| ○ SCC with pseudosarcomatous traits | 2 | 17 |
| Previous therapies: | ||
| • Surgery | 12 | 100 |
| • Radiotherapy | 6 | 50 |
| • Chemotherapy | 1 | 8 |
| • TKI | 1 | 8 |
| • Sirolimus | 1 | 8 |
| • Metastasectomy | 1 | 8 |
| • CTRT | 1 | 8 |
| Chemotherapy associated with cetuximab: | ||
| • Cisplatin | 4 | 33 |
| • Carboplatin | 7 | 58 |
| • Cisplatin + 5-fluoruracil | 1 | 8 |